Osteoporosis

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
JAMA 2016;316:722-733. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators.

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Mayo Clin Proc 2017;92:200-210. Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D

Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.
J Bone Miner Res 2017;32:17-23. Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM

Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.
Endocrinology 2016;157:141-149. Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Endocrinol Metab 2015;100:697-706. Leder BZ, O’Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G. J Clin

Effects of Abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial.
Bone 2016 Nov 5 [Epub ahead of print]. Moreira C, Fitzpatrick LA, Wang Y, Recker RR.

One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.
J Bone Miner Res 2017;32:24-33. Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G.

One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.
Bone 2017;95:143-150. Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G.

Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
Calcif Tissue Int 2016;99:489-499. Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G.